Search
About
You are currently browsing the Drug Kennel weblog archives for the day Saturday, February 28th, 2009.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Latest
- Failed 505(b)(2)?: Vivus’ Qnexa
- Will We Have Generic User Fees? Public Meeting To Be Held.
- Lannett’s Morphine Sulfate Oral Solution: 505(b)(2) or 505j?
- Generic Lovenox – 505j or 505(b)(2)
- New User Fees for 2011
- Still submitting paper ANDA applications?
- What should a license cost?
- Avandia: Who Won?
- Advisory Committee Meeting: Rosiglitazone
- The skinny on a potential new treatment of obesity
Generic Biologics
Published February 28th, 2009 in News Commentary. 0 CommentsThis past week I attended the 2009 Generic Pharmaceutical Association annual meeting. Much time was devoted to the issue of generic versions of biologics. Adding to the debate was the what to call these drugs. The GPhA prefers to call them biosimilars (nice ring to sameness) or biogenerics and BIO prefers to call them follow-on biologics [...]